Funder
Post-Finasteride Foundation
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference143 articles.
1. D.A. Finn, A.S. Beadles-Bohling, E.H. Beckley, M.M. Ford, K.R. Gililland, R.E. Gorin-Meyer, K.M. Wiren, A new look at the 5alpha-reductase inhibitor finasteride. Cns. Drug. Rev. 12(1), 53–76 (2006).
https://doi.org/10.1111/j.1527-3458.2006.00053.x
2. A.M. Traish, R.C. Melcangi, M. Bortolato, L.M. Garcia-Segura, M. Zitzmann, Adverse effects of 5alpha-reductase inhibitors: what do we know, don’t know, and need to know?. Rev. Endocr. Metab. Disord. 16, 177–198 (2015).
https://doi.org/10.1007/s11154-015-9319-y
3. K.D. Kaufman, E.A. Olsen, D. Whiting, R. Savin, R. DeVillez, W. Bergfeld, V.H. Price, D. Van Neste, J.L. Roberts, M. Hordinsky, J. Shapiro, B. Binkowitz, G.J. Gormley, , Finasteride in the treatment of men with androgenetic alopecia. Finasteride male pattern hair loss study group. J. Am. Acad. Dermatol. 39(4 Pt 1), 578–589 (1998). https://doi.org/S0190-9622(98)70007-6
4. S.V. Frye, H.N. Bramson, D.J. Hermann, F.W. Lee, A.K. Sinhababu, G. Tian, Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm. Biotechnol. 11, 393–422 (1998)
5. J.C. Nickel, Y. Fradet, R.C. Boake, P.J. Pommerville, J.P. Perreault, S.K. Afridi, M.M. Elhilali, Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 155(9), 1251–1259 (1996)